Efficacy of a Herbal Formula for Bone Metastases
Bone Metastases
About this trial
This is an interventional supportive care trial for Bone Metastases
Eligibility Criteria
Inclusion Criteria: Aged 18 years or older Breast cancer bone metastasis-no supplementary treatment or hormonal treatment alone Confirmed diagnosis of metastatic breast cancer Radiographic proof of metastatic bone disease Informed consent obtained Exclusion Criteria: Known history of primary bone tumors (benign and/or malignant) Prior use of bone modifying agents, including but not limited to zoledronic acid or denosumab within 12 months of study entry Active anti-cancer therapies in the form of cytotoxics or targeted therapies. [Patients who are currently on hormonal therapies, including but not limited to tamoxifen, aromatase inhibitors and LHRH agonists/antagonists are allowed for study entry. Clarifications shall be sought from investigators if in doubt]. Significant drug hypersensitivity No informed consent signed
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Study group
Control group
Herbal formula 5g daily, and Zometa
Zometa alone